<DOC>
	<DOCNO>NCT00630799</DOCNO>
	<brief_summary>This multi-center , open-label study 2 dos leuprolide acetate 17 mg depot , administer three month apart , subject prostate cancer might benefit medical androgen deprivation therapy</brief_summary>
	<brief_title>Efficacy Safety Study New Leuprolide Acetate 17 mg Depot Treat Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Males 18 year age , histologically proven carcinoma prostate , might benefit medical androgen deprivation therapy ; life expectancy least 1 year ; WHO/ECOG performance status 0 , 1 , 2 ; adequate renal function screening define serum creatinine &lt; = 1.6 time upper limit normal ( ULN ) clinical laboratory ; adequate stable hepatic function define bilirubin &lt; = 1.5 time ULN transaminase ( i.e . SGOT , SGPT ) &lt; = 2.5 time ULN clinical laboratory screening ; ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate Investigator comply requirement entire study ; sign write informed consent prior inclusion study . Evidence brain metastasis , opinion Investigator , take account medical history , clinical observation symptom ; evidence spinal cord compression , opinion Investigator , take account medical history , clinical observation symptom ; evidence severe urinary tract obstruction threaten urinary retention , opinion Investigator , take account medical history , clinical observation symptom ; presence tumor immediate vicinity could cause cord compression , opinion Investigator , take account medical history clinical observation ; excruciate , severe pain extensive osseous deposit , opinion Investigator , take account medical history , clinical observation symptom ; testosterone level &lt; = 1.5 ng/mL screening , locally determine laboratory clinical site ; previous cancer systemic therapy chemotherapy , immunotherapy ( e.g . antibody therapy , tumorvaccines ) , biological response modifier ( e.g . cytokine ) within 3 month baseline ; previous hormonal therapy treatment prostate cancer , LHRH analogue ( e.g . Lupron® , Zoladex® , etc . ) ( washout allow ) ; previous treatment ARreceptor blocker , Casodex® , Fugerel® , Megace® , Androcur® ( washout allow ) ; previous orchiectomy , adrenalectomy hypophysectomy ; previous prostatic surgery ( e.g . radical prostatectomy , transurethral resection prostate ( TURP ) within 2 week prior baseline ; previous local therapy primary tumor curative attempt surgery ( external beam radiotherapy , brachytherapy , thermotherapy , cryotherapy ) within 2 week prior baseline ; investigational drug within 5 halflives physiological action 3 month , whichever longer , baseline ; administration 5αreductase inhibitor ( Proscar® , Avodart® , Propecia® ) within 3 month baseline ; overthecounter ( OTC ) alternative medical therapy estrogenic antiandrogenic effect ( i.e. , PCSPES , saw palmetto , Glycyrrhiza® , Urinozinc® , DHEA ) within 3 month baseline ; hematological parameter ( RBC , total differential WBC count , platelet count , hemoglobin , hematocrit ) outside 20 % upper low limit normal ( ULN , LLN ) clinical laboratory screening ; coexistent malignancy , accord Investigator 's opinion ; uncontrolled congestive heart failure , myocardial infarction coronary vascular procedure ( e.g . balloon angioplasty , coronary artery bypass graft ) significant symptomatic cardiovascular disease ( ) within 6 month baseline ; rest uncontrolled hypertension : &gt; =160/100 mmHg ) symptomatic hypotension within 3 month baseline ; venous thrombosis within 6 month baseline ; uncontrolled diabetes ( patient uncontrolled diabetes need compensate metabolic disorder treatment LHRH analogue ) ; history drug and/or alcohol abuse within 6 month baseline ; serious concomitant illness ( e ) disease ( ) ( e.g. , hematological , renal , hepatic , respiratory , endocrine , psychiatric ) may interfere , put patient additional risk , ability receive treatment outline protocol ; patient anticoagulative therapy include warfarin ( Coumadin® ) heparin . Those patient low dose low molecular weight heparin may enrol study ; Abnormal coagulation study ( PT/PTT ) baseline . blood donations/losses within 2 month baseline , apart previous prostatic surgery patient ( see exclusion 10 ) ; know hypersensitivity GnRH , GnRH agonist , include LHRH analogue , excipients study formulation ; history follow prior study : immunization ( within 4 week baseline ) ; flu shot ( within 1 week baseline 1 week prior study drug administration ) ; anaphylaxis ; skin disease would interfere injection site evaluation ; dermatographism document screen follow treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
</DOC>